Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1

Exclusion Criteria

• •1. Uncontrolled ascites, uncontrolled hepatic encephalopathy, or uncontrolled esophageal/gastric varices
• •2. Co-infection with HIV or hepatitis B (HBV)
• •3. CPT 7 or above, or MELD \>10
• •4. Total bilirubin 4.0 mg/dL or above
• •5. CrCl (creatinine clearance) \< 30 mL/min
• •6. Any unstable active medical illnesses.
• •7. Active use of illicit substances, alcohol, or smoking.
• •8. Any malignancy within last 5 years except for basal cell skin cancer that has been adequately treated or HCC within Milan or UCSF criteria, which will be acceptable
• •9. Any prior treatment with direct acting antivirals (approved or investigational), including HCV protease inhibitors, such as SMV. Patients who received prior treatment with SOF, and/or NS5A inhibitors (e.g. ledipasvir or Daclatasvir) can be included in this study
• •10. Platelet \< 30 K/uL